Last reviewed · How we verify
Oral doxycycline hyclate
Doxycycline hyclate is a tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.
Doxycycline hyclate is a tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Used for Bacterial infections (respiratory tract, urinary tract, skin and soft tissue), Acne vulgaris, Rosacea.
At a glance
| Generic name | Oral doxycycline hyclate |
|---|---|
| Sponsor | Galderma R&D |
| Drug class | Tetracycline antibiotic |
| Target | Bacterial 30S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Doxycycline hyclate works by blocking bacterial protein synthesis through reversible binding to the bacterial 30S ribosomal subunit, preventing aminoacyl-tRNA from entering the A site. This broad-spectrum mechanism makes it effective against a wide range of gram-positive and gram-negative bacteria, as well as certain atypical organisms. At sub-antimicrobial doses, doxycycline also exhibits anti-inflammatory properties through inhibition of matrix metalloproteinases and modulation of immune responses.
Approved indications
- Bacterial infections (respiratory, urinary, skin, soft tissue)
- Acne vulgaris
- Rosacea
- Malaria prophylaxis
- Lyme disease
- Chlamydial infections
Common side effects
- Photosensitivity
- Nausea and vomiting
- Esophageal irritation
- Vaginal candidiasis
- Diarrhea
- Headache
Key clinical trials
- A Study of Doxycycline to Treat Chlamydial Infection (PHASE4)
- The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic Rosacea (NA)
- FuKe Qianjin Capsule Plus Antibiotics for Chronic Endometritis (PHASE4)
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Effects of Treatments on Atopic Dermatitis (PHASE2)
- Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib (PHASE2)
- Ocular Rosacea Biome Study (PHASE4)
- Dual Therapy With Vonoprazan Plus Amoxicillin or Doxycycline Versus Bismuth Quadruple Therapy for Helicobacter Pylori Eradication. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral doxycycline hyclate CI brief — competitive landscape report
- Oral doxycycline hyclate updates RSS · CI watch RSS
- Galderma R&D portfolio CI